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Background: Luminance contrast sensitivity and colour vision are considered to have great predictive value in the
evaluation of type 2 diabetic retinopathy. However, these two visual characteristics have seldom been investigated
in the same group of patients. In the present study we measured contrast sensitivity and colour vision in a group
of patients with type 2 diabetes and correlated the results with estimates of common metabolic markers for the
disease. A subgroup of the patients had no clinical signs of retinopathy.
Methods: The vision of 27 patients (n = 50 eyes) with type 2 diabetes, with retinopathy (n = 20 eyes), or without
retinopathy (n = 30 eyes) were evaluated using two psychophysical tests, the Farnsworth–Munsell 100 hue test
(FM 100), and measurements of the luminance contrast sensitivity at 11 spatial frequencies. The results were compared
with measurements obtained from an age-matched control group (n = 32), and were correlated with the level of
glycated haemoglobin, glycaemic level, and time of disease onset. Signs of retinopathy were identified during the
ophthalmological examinations.
Results: Contrast sensitivity and colour vision impairments were present at different levels in diabetes patients. Eyes
with retinopathy showed more severe vision loss than eyes without retinopathy. The FM 100 test was more sensitive
for separation of patients from controls. Colour vision loss had no colour axes preference. The contrast sensitivity test
appeared to have some advantage in differentiating patients with retinopathy from patients without retinopathy.
Conclusions: Both methods can be useful to follow the visual function of diabetic patients and should be
used together to discriminate patients from controls, as well as to identify early signs of retinal damage.
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Farnsworth–Munsell testBackground
The World Health Organization predicts that by the
year 2030, 350 million people will be suffering from type
2 diabetes, and their care will account for up to 15% of
the funds allocated to national healthcare [1,2]. Type 2
diabetes is a prominent cause of acquired blindness or
severe visual impairment [3,4], and diabetic microvascu-
lar complications affecting the retina lead to a form of
retinopathy that could be very detrimental to a patient’s
life [5-7]. These complications generally increase the* Correspondence: mitcortes@unifap.br
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functions [8].
Diabetic retinopathy is characterized by progressive
changes in the structure of the retinal microvasculature.
It can lead to the development of micro aneurysms, hae-
morrhages, ischaemia, and poor retinal perfusion [9].
Together, these defects can lead to retinal neurodegener-
ation that occurs in diabetes [10].
Usually, the evaluation of retinopathy is performed by
examination of the eye fundus, but before the establish-
ment of visible anatomical fundoscopic changes, the visual
function was used as an indicator of underlying neuronal
loss [11]. In addition, psychophysical procedures have beenl Ltd. This is an Open Access article distributed under the terms of the Creative
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ing from diabetes [12-17].
Visual acuity has been extensively used as a noninva-
sive indicator of visual function [18,19], and it is well
known that it can be affected in diabetes. However, vis-
ual acuity changes cannot always be used to differentiate
the visual function of eyes with and without established
retinopathy [3]. Moreover, visual acuity measurements
provide only limited evaluations of the subject’s spatial
vision. Visual acuity is correlated with high spatial fre-
quency cutoff of the luminance spatial contrast sensitiv-
ity function, and represents the highest spatial frequency
that a subject sees at high contrast. As shown in previ-
ous studies, visual acuity can be preserved in some cases
of diabetes, while at the same time intermediate and low
spatial frequencies may show severe contrast sensitivity
decreases [3]. In addition, it has been shown that retin-
opathy caused by diabetes increased the range of spatial
frequencies with impaired contrast sensitivity [13].
Colour vision evaluation is another important tool
used to monitor the visual function of patients with dia-
betes. Several colour vision tests are available, including
measurements of the patient’s ability to perform colour
arrangement, estimates of colour discrimination thresh-
olds, and measurements of colour contrast sensitivity.
The Farnsworth–Munsell 100 hue test (FM 100 test) is a
colour arrangement test that has been used for colour
vision evaluation in diabetes and other diseases that
affect the visual system. Initial studies of diabetic pa-
tients showed high FM 100 scores, especially along the
blue-yellow axis [4]. An investigation of the colour vi-
sion in 2701 patients enrolled in the Early Treatment
Diabetic Retinopathy Study, using the FM 100 test,
showed blue-yellow losses that were correlated in mag-
nitude with the severity of macular oedema, but there
were also colour vision losses in patients without macu-
lar oedema [20]. In a study of diabetic patients without
retinopathy using another colour arrangement test, the
Lanthony Desaturated D-15d, it was found that deficits
were restricted to the tritan axis [21]. The colour dis-
crimination ellipses of the same group of diabetic pa-
tients estimated with the Cambridge Colour Test (CCT)
showed diffuse losses [21-23]. Diabetic patients evalu-
ated by Colour Assessment and Diagnosis tests (CAD)
also showed diffuse colour vision losses [24].
All these findings indicated that psychophysical evalu-
ation of luminance contrast sensitivity and colour vision
are important tools for the screening of visual function
deficits in diabetic patients, but there are some aspects
that need further clarification. Colour vision and con-
trast sensitivity impairment could be used to identify
retinopathy at earlier stages. These two procedures
should be further studied to determine their specificity
and sensitivity for diabetic retinopathy evaluations. Themechanisms that support the results of both tests should
be different. For contrast sensitivity measurements, the vis-
ual response is mediated by mechanisms working within
threshold levels, while for colour vision evaluation esti-
mated using the Farnsworth–Munsell 100 hue test, there
are many additional mechanisms working at suprathres-
hold levels. Therefore, both tests could show different or
complementary neural impairment.
It would also be important to establish the correlation
between results obtained with psychophysical methods
and information provided by metabolic markers. Previ-
ously, it was reported that although the investigations of
contrast sensitivity and colour vision successfully differ-
entiated nondiabetic subjects from diabetic patients with-
out retinopathy, they were not adequate to separate
patients with and without retinopathy [25].
In this study, we evaluated the luminance contrast
sensitivity across a wide range of spatial frequencies and
measured the ability of subjects to perform colour ar-
rangements using the FM 100 test on a group of patients
with type 2 diabetes, with and without retinopathy. We
analysed the psychophysical results, and correlated these
results with the levels of metabolic markers for the dis-
ease and with the time elapsed since disease diagnosis.
Methods
Subjects
We tested both eyes of 59 subjects, including 32 healthy
subjects (64 eyes, 49 ± 12.3 years old) and 27 patients
with type 2 diabetes (54 eyes, 53 ± 12.1 years old). In the
type 2 diabetic group, 4 eyes of different subjects were
later excluded from this study because they met the ex-
clusion criteria that were applied, 20 eyes had nonproli-
ferative retinopathy, and 30 eyes had no retinopathy.
The criteria to diagnose retinopathy followed the inter-
national recommendations [26].
Subjects were recruited through the Program for the
Control of Diabetes and Hypertension of the Health
Basic Centre of the Federal University of Amapá, Macapá,
Brazil. All procedures were approved by the Ethical
Committee for Research in Humans of the Federal
University of Amapá (Protocol #FR-278871/09).
All patients were interviewed by an endocrinologist
regarding their health and clinical history. All patients
were also examined by an ophthalmologist before starting
the psychophysical tests. The ophthalmological exams in-
cluded tonometry, visual acuity measurement, evaluations
of eye refractive state, retinography, and fundoscopy. In
addition, the Ishihara plates test was applied as a screening
procedure to identify subjects with some degree of red-
green colour vision loss.
Exclusion criteria included visual acuity of 20/40 or
worse, congenital colour blindness, history of ophthal-
mological disease, advanced cataracts, and/or any chronic
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visual system. None of the patients had previously received
laser photocoagulation treatment.
Psychophysical procedures
The contrast sensitivity test and the FM 100 test were
implemented using an IBM desktop computer equipped
with a graphics card. All stimuli were displayed on a
21-inch colour LCD monitor (spatial resolution of
1280 × 1200 pixels, 75 Hz, 8 bits, Ecofit P2270 model;
Samsung, Seoul, South Korea) in a dark room. A dither-
ing routine was used to obtain additional grey levels [27].
Luminance linearization was performed by gamma cor-
rection using a colorimeter (CS100-A; Konica Minolta,
Osaka, Japan).
For the contrast sensitivity tests, the subject was posi-
tioned at a 3 m distance from the monitor. The contrast
sensitivity was estimated for eleven spatial frequencies,
0.2, 0.5, 0.8, 1, 2, 4, 6, 10, 15, 20, and 30 cycles per de-
gree (cpd), using vertical sinusoidal gratings in a field of
6° × 5° of visual angle and 43.5 cd/m2 mean luminance.
The contrast threshold was estimated by using the
method of adjustment starting from subthreshold con-
trast levels [28]. As the investigator increased the stimu-
lus contrast, the subject’s task was to detect the grating
presence on the screen and verbally inform the investi-
gator. The contrast was then decreased until the subject
reported that the stimulus was no longer detectable.
This procedure was repeated 10 times, and the mini-
mum perceived stimulus contrast was considered to be
the contrast threshold. The contrast sensitivity was then
estimated by the log10 of the inverse of contrast thresh-
old value for each spatial frequency.
For the FM 100 test, the subject was positioned at a
1 m distance from the monitor. The stimulus was com-
posed of 85 circles of different hues, saturated colours,
1° of visual angle, and 42 cd/m2 of luminance. The com-
puterized test was equivalent to the original test illumi-
nated by D65, and was previously applied in other clinical
investigations [27,29]. Initially, the stimulus was shown to
the subject as an ordered sequence of hues. Afterwards,
the circles were mixed and randomly distributed through-
out the monitor screen. The subject’s task was to re-
arrange the circles following a sequence of hues as similar
as possible to what was previously shown. There was no
time limit to perform the task. The errors in task perform-
ance were quantified and recorded as the log10 of the total
score. The log-transformation in both the results of con-
trast sensitivity test and the FM 100 hue test were used to
meet the assumptions of parametric statistical tests [27].
Data analysis
The normative data of the psychophysical results were
calculated by the tolerance intervals analysis with a 95%confidence level for 90% of the population. One- and
two-way analysis of variance with a Tukey’s post-hoc
test (with α = 0.05) were used to compare patients’ re-
sults with those obtained from control subjects. The
results of the psychophysical evaluation were corre-
lated with the time of the disease when it was initially
diagnosed, fasting blood glucose level, and glycated
haemoglobin level, by using the linear correlation method
(with α = 0.05).
Results
Ophthalmological exam and evaluation with Ishihara
colour plates
All subjects from the control group and type 2 diabetic
group had normal trichromatic colour vision in the
Ishihara plate test. Twenty out of 50 eyes were diagnosed
with retinopathy, comprising 13 eyes with no prolifera-
tive retinopathy, six eyes with proliferative retinopathy,
and one eye with retinopathy associated with macular
degeneration.
Among the eyes from type 2 diabetic patients without
retinopathy, five eyes had increased intraocular pressure
(22 mmHg), six eyes had visual acuity worse than 20/20,
and two eyes showed anatomical changes, including one
eye with keratosis and one eye with papillary injury.
Among the eyes from type 2 diabetic patients with ret-
inopathy, four eyes had increased intraocular pressure
(30 mmHg), 10 eyes had visual acuity worse than 20/20,
and six eyes showed anatomical changes, including five
eyes with opacity of ocular media and one eye with iris
atrophy.
Clinical evaluation
The mean fasting blood glucose and glycated haemoglo-
bin for the group of diabetic patients were 136.69 ±
56.81 mg/dl and 7.5% NGSP ± 1.19, respectively (NGSP:
National Glycohaemoglobin Standardisations Program)
[30]. The mean time elapsed since diabetes diagnosis
was 6.69 ± 7.42 months. The mean time elapsed since
diabetes diagnosis was similar between the type 2 diabetic
patients without retinopathy (6 ± 7 months) and the
type 2 diabetic patients with retinopathy (6 ± 7 months)
(p = 0.22).
Contrast sensitivity
Table 1 shows the range of tolerance intervals for the
control group estimated from the contrast sensitivity
test. Monocular luminance contrast sensitivity was lower
than the normal tolerance limits in at least one spatial
frequency in a large proportion of diabetic patients: 31
of 50 eyes from patients with type 2 diabetes; 13 of 30
eyes from patients with type 2 diabetes without retinop-
athy; and 11 of 20 eyes from patients with type 2 dia-
betes with retinopathy (Table 1).
Table 1 Normal range for contrast sensitivity test and FM 100 scores estimated from a control group
Contrast sensitivity (log10) FM 100 score (log10)
0.2 cpd 0.5 cpd 0.8 cpd 1 cpd 2 cpd 4 cpd 6 cpd 10 cpd 15 cpd 20 cpd 30 cpd
UTL 1.61 2.34 2.33 2.59 2.73 2.75 2.81 2.49 2.09 1.71 1.03 1.88
LTL 0.53 1.1 1.31 1.45 1.73 1.78 1.39 0.96 0.5 0.2 0.23 1.73
Number of eyes with impaired results compared with the tolerance intervals
Contrast sensitivity (log10) FM 100 score (log10)
0.2 cpd 0.5 cpd 0.8 cpd 1 cpd 2 cpd 4 cpd 6 cpd 10 cpd 15 cpd 20 cpd 30 cpd
DM2 NR 2 1 4 4 5 11 9 5 6 9 0 26
DM2 WR 0 1 3 2 7 11 7 6 4 6 0 18
UTL = upper tolerance limit, LTL = lower tolerance limit, DM2 NR = type 2 diabetic patients with no retinopathy, DM2 WR = type 2 diabetic patients
with retinopathy.
Figure 1 Means and standard deviations for monocular
luminance contrast sensitivity of controls and diabetic patients.
(A) Controls (filled circles) versus diabetic patients without
retinopathy (empty diamonds). (B) Controls (filled circles) versus
diabetic patients with retinopathy (empty squares). Controls had
higher contrast sensitivity than diabetics in all conditions measured,
but the level of significance (p < 0.05) was reached only in the
conditions marked with asterisks (*). There was contrast sensitivity
attenuation at 15 and 20 cpd for patients without retinopathy, and
in the range between 0.5 and 30 cpd for patients with retinopathy.
There was no statistical difference between the two diabetic groups
in any spatial frequency. DM 2: type 2 diabetes.
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had lower mean monocular contrast sensitivity at all
spatial frequencies than the control group, but the differ-
ence only reached statistical significance in two out of
11 spatial frequencies tested, 15 and 30 cpd (p < 0.05).
The group of diabetic patients with retinopathy also had
lower mean monocular contrast sensitivity than the con-
trol group, at all spatial frequencies, but the difference
was statistically significant at 0.5, 0.8, 2, 4, 6, 10, 15, 20,
and 30 cpd (p < 0.05), which was nine of 11 spatial fre-
quencies studied. Figure 1 shows means and standard
deviations for contrast sensitivity at all spatial frequen-
cies for the two groups of diabetic patients, and com-
pares the results with values obtained from control
subjects.
Colour vision
Table 1 shows the range of tolerance intervals for the
control group, estimated from the FM 100 test. The
ability of diabetic patients to perform the FM 100 hue
arrangement test, using their monocular vision with ei-
ther eye, was impaired in 44 out of the 50 eyes of type
2 diabetic patients tested, and they had FM 100 error
scores above the normal tolerance limits (Table 1). The
errors of diabetic patients were diffusely distributed
across the FM 100 colour diagram without a specific
colour axis preference. Figure 2A-C shows, respectively,
the individual results for three controls, three patients
without retinopathy, and three patients with retinop-
athy. The type 2 diabetic group without retinopathy
had 26 eyes out of 30 with scores above the normal tol-
erance limits, while the retinopathy group had 18 eyes
out of 20 with scores above the normal limits. Figure 2D
shows the comparison of monocular performance in
the FM 100 test between normal controls, diabetic pa-
tients without retinopathy, and diabetic patients with
retinopathy. Both groups of diabetic patients differed
Figure 2 Monocular colour vision of diabetic patients evaluated with the FM 100 hue arrangement test (A-C). Individual results for three
subjects of each group: (A) controls, (B) diabetic patients without retinopathy, and (C) diabetic patients with retinopathy. Diabetic patients made
more mistakes than controls, but the errors were diffusely located in the FM 100 colour space without preference for any colour vision axis.
(D) Box plots of the FM 100 error scores (log10 values). The control group made smaller numbers of mistakes than the two diabetic groups
(p < 0.05). There was no difference between diabetic groups. DM 2: type 2 diabetes. Q1: First quartile. Q3: Third quartile. R = red, Y = yellow,
G = green, B = blue, P = purple.
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each other (p > 0.05).
Correlations among the groups
There were moderate correlations between time of diag-
nosis and contrast sensitivity, ranging from 2 to 10 cpd
for the eyes with no retinopathy, and at 0.8 cpd for the
eyes with retinopathy. There was a moderate correlationbetween glycated haemoglobin level and contrast sensi-
tivity at 0.2 cpd for eyes with no retinopathy, and at 0.2,
0.8, and 2 cpd for eyes with retinopathy. There was a
correlation between fasting blood glucose level and con-
trast sensitivity at 0.2, 0.5, and 0.8 cpd for eyes with no
retinopathy, but there was no correlation between fast-
ing blood glucose level and contrast sensitivity at any
spatial frequency for eyes with retinopathy. There was
Andrade et al. BMC Ophthalmology 2014, 14:104 Page 6 of 10
http://www.biomedcentral.com/1471-2415/14/104no significant correlation between time of diagnosis,
fasting blood glucose level, and glycated haemoglobin
level with FM 100 scores.
Figure 3A–C shows the correlation between the con-
trast sensitivity peak value (CSF peak) and the number
of mistakes made in the FM 100 test (FM 100 score).
We used the least squares method to obtain the regression
straight lines across the data, expressed in log10 scales.
There were moderate correlations for the three groups,
which were higher for control subjects (r = −0.46, p < 0.01),
and patients with retinopathy (r = −0.59, p < 0.01), and
lower for patients with no retinopathy (r = 0.36, p < 0.05).
The Khachiyan Ellipsoid Method [31] was used to fit
the best ellipses to the data points corresponding to con-
trols (Figure 3A), diabetic patients without retinopathy
(Figure 3B), and diabetic patients with retinopathy
(Figure 3C). Then, the ellipses representing the three
groups were compared as shown in Figure 3D. Diabetic
group ellipses are higher in the diagram than control el-
lipses owing to their larger FM 100 scores. The ellipse
from the diabetic patients with retinopathy is displaced
to the left in the diagram, in comparison with the ellipses
from diabetic patients without retinopathy, and from
controls owing to their lower contrast sensitivity peaks.
Discussion
It has been reported that psychophysical measurements
are useful for monitoring the effects of diabetes on the
visual system. Several studies identified visual losses of
contrast sensitivity and colour vision associated with
diabetes in the presence or absence of retinopathy, and
used visual function as a biomarker to indicate the dia-
betic disease status [3,4,20-24].
In this study we analysed two commonly used visual
tests to evaluate the visual functions of diabetic patients.
Both tests have advantages and disadvantages that apply
to diabetic patients. An important disadvantage is that
both tests required long testing time periods and were
very demanding in terms of the patient’s attention and
commitment. These factors may have contributed to the
data variability. However, the visual tests have been ap-
plied in several studies, and our results could be directly
compared with previously reported results. Few studies
have incorporated both tests and correlated each result
for the same patient groups. We suggest that our find-
ings were important because they showed that patients
without retinopathy may develop visual function impair-
ment even before the clinical symptoms appear, and that
contrast sensitivity and colour vision results can be used
as clinical measurements to identify the status of the vis-
ual function of the newly diagnosed diabetic patient.
As previously reported, we found that diabetic patients
with retinopathy had worse results compared with pa-
tients without retinopathy and compared with controlsubjects. The visual impairment of eyes with retinopathy
was due to retinal neurodegeneration caused by diabetes
[32]. It was shown to be related to mitochondrial dys-
function, retinal capillary death, and formation of acellu-
lar capillaries [33,34].
Our results showed similar monocular luminance con-
trast sensitivity estimated from eyes without retinopathy
and control eyes for the majority of spatial frequencies
that were studied. In contrast, the eyes with retinopathy
showed a decrease in monocular luminance contrast
sensitivity throughout the entire spatial frequency do-
main. These results were similar to those of Sokol et al.
[13], while other studies showed that, even in eyes with-
out retinopathy, there was a contrast sensitivity decrease
in a wide range of spatial frequencies [35,36]. We sug-
gest that the differences in these results, when compared
with others, may be due to differences in patient eyes
and/or time from diagnosis.
For the investigation of luminance contrast sensitivity,
we used sinusoidal gratings at several spatial frequencies
as stimuli to detect the contrast threshold. Other studies
with diabetic patients applied different stimuli configura-
tions to estimate contrast threshold [25,37-40]. However,
the use of sinusoidal grating was important because the
visual system had different channels for spatial frequency
processing. It is still not clear which channels would be
impaired in diabetics. Different studies showed deficits
in the contrast sensitivity estimated at different ranges
of spatial frequency [14,16,41]. In diabetic patients, the
reduction of the contrast sensitivity occurred even when
the visual acuity was preserved [42,43].
In this study, the diabetic patients as a group showed
higher FM 100 scores than controls, but the FM 100 test
was not able to differentiate the diabetic group with ret-
inopathy from the diabetic group without retinopathy.
The errors performed by diabetic patients, in the hue
arrangement test, had no chromatic axis preference.
There have been conflicting reports regarding axis pref-
erence in diabetic colour vision loss. Many studies that
used the FM 100 test to evaluate the colour vision of
diabetic patients reported preferential losses in the blue-
yellow axis [4,20,44-50], but there were other studies
using the same test that showed no colour axis prefer-
ence [14]. In addition, diffuse losses were reported by
measuring colour discrimination thresholds [22] or by
evaluating individual colour spaces [51]. Studies also
found that the colour vision of the same group of dia-
betic patients without clinical signs of retinopathy could
be measured by hue arrangement ability with the D-15d
test, and their colour discrimination thresholds could be
determined with the CCT. Tritan axis losses were found
in the hue arrangement test and diffuse losses were
found in the discrimination thresholds [21]. Using CCT,
it was found that colour discrimination losses were
Figure 3 Correlation between contrast sensitivity peak value
and number of mistakes made in the FM 100 hue arrangement
test. Psychophysical tests were performed using monocular vision.
Contrast sensitivity peak value and number of FM 100 mistakes were
plotted using a log10 scale. (A-C) Data points were fitted with linear
regressions using the least square method: (A) controls, (B) diabetics
patients without retinopathy, and (C) diabetic patients with retinopathy.
There were moderately significant linear correlations between the FM
100 score and CSF peak for the three groups of subjects, but correlation
was higher for controls (A) and diabetic patients with retinopathy (C)
than for diabetic patients without retinopathy (B). (D) Data points were
fitted with ellipses using the Khachiyan Ellipsoid Method: (a) controls, (b)
diabetic patients without retinopathy, and (c) diabetic patients with
retinopathy. Diabetic ellipses are higher in the diagram than the control
ellipse owing to their larger FM 100 scores. The ellipse from the diabetic
patients with retinopathy is displaced to the left in the diagram in
comparison with the ellipses from diabetic patients without retinopathy
and from controls, owing to their lower contrast sensitivity peaks.
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diabetic patients without retinopathy [23]. In another
study using the colour vision assessment (CAD) test it
was observed that diabetic subjects exhibited equal and
highly correlated reduction in red-green and blue-yellow
thresholds [24]. It may not be possible to directly com-
pare the results from FM100 with other tests such as
CCT and CAD. The task in FM100 is performed at
suprathreshold levels, while for CAD and CCT the final
results are estimated for the threshold level. CAD and
CCT investigate the functioning of cells or neuronal
processing with highest sensitivity, while in the FM100
test it is possible that more cells or neuronal processes
than those with high sensitivity may contribute to the
patient’s performance.
Previously, other investigations used luminance sinus-
oidal gratings and FM 100 tests to estimate contrast sen-
sitivity and colour vision of a group of diabetic patients
[14,35]. Trick et al. [14] showed that type 2 diabetic pa-
tients without retinopathy, with little retinopathy, or
with well-developed retinopathy had decreased contrast
sensitivity in the intermediate range of spatial frequen-
cies, and showed diffuse colour vision losses. They also
reported that contrast sensitivity loss was more preva-
lent than impoverished hue discrimination among dia-
betic patients. Malukiewicz et al. [35] showed contrast
sensitivity losses at intermediate and high spatial fre-
quencies in type 2 diabetic patients. In addition, they
evaluated patients’ colour vision by anomaloscopy and
found colour vision losses, especially along the tritan
axis.
Because the interpretation of the contrast sensitivity
test and the FM100 hue test results in diabetic patients
with and without retinopathy are still controversial, we
correlated the results of both tests in the same group of
diabetic patients and in controls, to evaluate how the
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patients with retinopathy had higher significant linear
correlations in a two-dimensional space having FM 100
scores and CSF peaks as parameters, but data from pa-
tients without retinopathy were less significantly corre-
lated (Figure 3). The main differences between controls
and patients with retinopathy were that data from con-
trols were located in the lower and middle regions of the
diagram, while data from patients were located in the
middle and upper regions of the diagram. The ellipses
represented the area where most of the results for each
group of patients could be found. We observed an over-
lapping area in the results from two-dimensional space,
which we considered as an intermediate risk area for a
newly diagnosed patient. The areas without overlap be-
tween the groups could be considered to indicate high
(exclusive diabetic area) or low (exclusive control area)
risk to develop visual loss due to diabetes. The results
for patients without retinopathy suggested an intermedi-
ate level between controls and patients with retinopathy,
indicating that the retinal damage was progressing, but
differences could not be resolved using conventional
ophthalmoscopy.
There has been no previous study showing the correl-
ation between the FM 100 test score and contrast sensi-
tivity peak for diabetic patients. This approach might be
valuable for a variety of studies including those that
measure contrast sensitivity by using methods other
than sinusoidal gratings [17,52].
We found better correlations between the levels of
metabolic parameters or time of diabetes diagnosis and
monocular contrast sensitivity of diabetic patients with-
out retinopathy, than among all the other parameters.
However, there was no complete correlation between
metabolic markers and psychophysical performance.
Previous studies reported both positive and negative cor-
relations between the level of metabolic markers and
psychophysical parameters [14,17,24,44] while others
found no correlation [53]. The variability of the clinical
status from patients investigated across the different
studies makes it more difficult to draw conclusions
about the significance of these correlations. Higher
values for time of diagnosis, glycated haemoglobin levels,
or fasting blood glucose indicated poor control of glucose
levels and this could be associated with a higher risk
of vascular damage [54]. We found more significant corre-
lations between contrast sensitivity and the metabolic
markers from eyes without retinopathy. In addition, we
found that the higher the value for metabolic markers, the
worse the psychophysical performance. The impairment
of glycaemic control alters neuronal function by both dir-
ect and indirect mechanisms. It is therefore possible that
in eyes with retinopathy, the correlations between the vis-
ual performance and levels of metabolic markers could benonlinear. Once the retinal damage occurs and the visual
function is lost, glycaemic control may have less influence
on the residual visual functions.
Conclusions
Measurements of contrast sensitivity and colour vision
ability of diabetic patients are important parameters to
monitor how the disease progresses and how it impairs
visual systems. Contrast sensitivity evaluations were use-
ful to distinguish diabetics with and without retinopathy,
but were not able to differentiate patients without retin-
opathy from controls. The FM 100 test was useful to dis-
tinguish diabetics from controls, but not diabetics with
and without retinopathy. We also concluded that the use
of two-dimensional spaces relating colour vision per-
formance and contrast sensitivity might be useful to
show the transition from normal vision to the vision of
patients without retinopathy, and to the impaired vision
of patients with retinopathy.
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